Rational design of an NLRP3 inhibitor with superior efficacy and safety for gout therapy
{{output}}
Gout, driven by urate crystal-induced inflammation, remains a therapeutic challenge due to the limited efficacy and toxicity of current treatments. Targeting the NLRP3 inflammasome, a central driver of gout pathogenesis, offers a promising strategy. While MCC9... ...
